Table 3.
Remdesivir therapy and other drugs used in remdesivir-treated patients during Delta and Omicron waves.
| Parameters | Delta (n = 490) | Omicron (n = 272) | p |
|---|---|---|---|
| Time between onset of symptoms and start of the antiviral treatment, mean ± SD (min–max) | 5.1 ± 3.0 (0–21) n = 479 |
3.5 ± 2.2 (0–14) n = 266 |
<0.001 |
| Patient treated within 5 days of symptoms, % (n) | 57.2 (274/479) | 86.8 (231/266) | <0.001 |
| Patient treated within 3 days of symptoms, % (n) | 27.8 (133/479) | 53.4 (142/266) | <0.001 |
| Immunomodulators, % (n) | 56.3 (276) | 55.9 (152) | >0.05 |
| Tocilizumab | 14.9 (73) | 9.6 (26) | 0.04 |
| Dexamethason | 49.6 (243) | 54.4 (148) | >0.05 |
| Baricitinib | 1.2 (6) | 3.3 (9) | 0.04 |
| Antibiotics, % (n) | 34.1 (167) | 41.2 (112) | 0.05 |
| Low molecular weight heparin in prophylactic dose, % (n) | 73.1 (358) | 73.5 (200) | >0.05 |
| Low molecular weight heparin in a therapeutic dose, % (n) | 16.9 (83) | 23.5 (64) | 0.03 |
Abbreviations: SD, standard deviation.